Sulfonated Reverse Thermal Gel for Protein Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein delivery systems, particularly those mimicking heparin, face challenges such as modification difficulties, susceptibility to desulfation, batch-to-batch variability, and adverse side effects, as well as the need for invasive surgeries for implantation, which limits their effectiveness and biocompatibility.
Innovation Solution
A heparin-mimicking sulfonated reverse thermal gel (SRTG) is developed, composed of a sulfonated graft copolymer that undergoes a sol-gel phase transition with temperature changes, allowing for non-invasive protein delivery while maintaining biocompatibility and stability, using poly(serinol hexamethylene urea)-co-poly(N-isopropylacrylamide) as the primary components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heparin is used as a protein delivery system, then heparin-binding protein stability is improved, but batch-to-batch variability and susceptibility to desulfation worsen
Solution Approach 1:
The patent creates a synthetic polymer copy of heparin's essential functional groups (sulfonate groups) without using actual heparin. The sulfonated poly(ethylene glycol) polymer mimics heparin's ability to bind positively charged proteins through electrostatic interactions, while avoiding heparin's structural instability, desulfation susceptibility, and batch-to-batch variability.
Solution Approach 2:
The patent changes the chemical parameters by replacing the complex natural heparin structure with a simplified synthetic polymer structure containing sulfonate groups. This parameter change maintains the essential electrostatic binding function while eliminating the structural instability and variability inherent in natural heparin.
2Reliability
If heparin-conjugated delivery systems are used, then protein delivery is improved, but adverse side effects and cell growth inhibition worsen
Solution Approach 1:
The patent extracts only the essential functional component of heparin (the sulfonate groups for electrostatic binding) while leaving behind the problematic components. The synthetic sulfonated polymer provides the necessary protein binding and delivery function without the adverse biological effects associated with natural heparin.
Solution Approach 2:
The patent uses a synthetic polymer that can be precisely controlled and standardized, replacing the variable natural heparin. This synthetic approach allows for consistent, reproducible delivery systems without the biological variability and adverse effects of natural polymers.
3Reliability
If bulk-sized sulfonated scaffolds are used, then heparin-like biofunction is achieved, but invasive surgery for implantation is required
Solution Approach 1:
The patent employs amphiphilic block copolymers that self-assemble into micellar structures with flexible, biocompatible coronas. These micelles can be administered systemically and accumulate at target sites, eliminating the need for invasive surgical implantation of bulk scaffolds while maintaining the heparin-like protein binding function.
Solution Approach 2:
The patent transitions from bulk-sized scaffolds (3D macroscopic structures requiring surgery) to nanoscale micelles (0D/1D structures that can be injected). This dimensional change allows the system to be administered through minimally invasive routes while preserving the essential electrostatic binding function.
4Ease of operation
If RTG transitions from sol to gel at body temperature, then non-invasive delivery is enabled, but control over gelation timing and location may be reduced
Solution Approach 1:
The patent uses temperature-responsive block copolymers that dynamically change their conformation and intermolecular interactions in response to temperature changes. Below the lower critical solution temperature (LCST), the polymers are soluble and form injectable solutions; above the LCST, they undergo phase separation and gelation, providing automatic temperature-driven control without complex external triggers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SRTG system enables sustained and controlled release of therapeutic proteins, preserves protein structure, and demonstrates excellent biocompatibility, overcoming the limitations of previous systems by providing a non-invasive delivery method that mimics heparin's biofunction at physiologically relevant temperatures.
Implementation Method 1
Temperature-responsive reverse thermal gels (RTG) are a group of stimuli-responsive biomaterials that have gained much attention in recent investigations. At room temperature, RTG systems exist in a solution state (sol) with low viscosity that allows injection through a small gauge needle. Upon reaching body temperature, the RTG transitions from a low-viscosity sol to a semi-solid gel (sol-gel phase transition).
Implementation Method 2
Heparin is a naturally sulfated biopolymer with an intrinsic negative charge. Heparin stores, protects and stabilizes positively charged heparin-binding proteins in the extracellular matrix (ECM). Sulfonation, or sulfation, of polymeric materials may induce a biofunction similar to that of heparin.
Data Source
AI summary
A heparin-mimicking sulfonated reverse thermal gel (SRTG) as a heparin-binding therapeutic protein delivery system. This system is designed to turn from low viscous liquid to a physical gel by exposure to body temperature alone. This allows direct deployment through a small gauge needle or catheter at target area with minimal surgical intervention. A unique aspect of this system is that it possesses a net negative charge due to the presence of sulfonate groups. This allows the SRTG to mimic heparin function, binding and preserving the bioactivity of positively charged therapeutic proteins, providing localized and sustained release of such proteins.